Phaseline

Targets › EPHA2

EPHA2 (Ephrin type-A receptor 2): drug programs, companies and trials

5 programs from 5 companies in 6 trials: 5 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. (UniProt, P29317)

Open in Phaseline: the race on EPHA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BicycleTxnuzefatide pevedotin (BT5528)
EphA2-targeting antibody-drug conjugate
EPHA2Phase 2Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumor Historically Known for High EphA2 ExpressionDec 2026
Chinese PLA General HospitalTP53-EphA-2-CAR-DC
TP53 mutant peptide-loaded, EphA2-targeting CAR dendritic cell vaccine
TP53, EPHA2Phase 1Solid Tumor, AdultDec 2026
M.D. Anderson Cancer CenterEphA2-targeting DOPC-encapsulated siRNA
EphA2 siRNA (gene silencing)
EPHA2Phase 1Advanced Malignant Solid NeoplasmApr 2027
Tianjin ConjuStar BiologicsSC-102
EphA2-targeting peptide conjugate with tubulin inhibitor
EPHA2Phase 1Advanced Solid CancersJun 2027
Mustafa Khasraw, MBChB, MD, FRCP, FRACPP30-EPS Vaccine
Peptide-based tumor-associated antigen vaccine targeting EphA2, CMV pp65, and Survivin lin
EPHA2, BIRC5Phase 1Glioma, MalignantFeb 2028

Conditions

Advanced Malignant Solid Neoplasm (1) Advanced Solid Cancers (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Advanced Solid Tumor Historically Known for High EphA2 Expression (1) Solid Tumor, Adult (1) Glioma, Malignant (1)

Modalities

mixed (2), other (1), small molecule (1), antibody (1)

Companies

M.D. Anderson Cancer Center (1) Tianjin ConjuStar Biologics (1) BicycleTx (1) Chinese PLA General Hospital (1) Mustafa Khasraw, MBChB, MD, FRCP, FRACP (1)

Related targets

TP53 (1) BIRC5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.